Generic placeholder image

Current Molecular Medicine

Author(s): Xueli Zhou, Panpan Wei , Xinju Wang, Jianguo Zhang and Yulin Shi *

DOI: 10.2174/1566524021666211004112055

DownloadDownload PDF Flyer Cite As
miR-141-3p Promotes the Cisplatin Sensitivity of Osteosarcoma Cell through Targeting the Glutaminase [GLS]-Mediated Glutamine Metabolism

Page: [177 - 184] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Aims: This study aimed to evaluate the roles and molecular targets of miRNA-141-3p in the cisplatin sensitivity of osteosarcoma.

Background: Osteosarcoma is one of the most common-type bone tumors, occurring mainly in children and adolescents. Cancer cells display dysregulated cellular metabolism, such as the abnormally elevated glutamine metabolism.

Objective: Non-coding RNA miRNA-141-3p has been reported to act as a tumor suppressor in osteosarcoma. Currently, the precise molecular mechanisms for the miR- 141-3p-mediated chemosensitivity through regulating glutamine metabolism remain unclear.

Methods: We collected thirty paired OS tumors and their adjacent normal tissues. The osteosarcoma cell lines [Saos-2] and normal osteoblast cells, hFOB1.19, were used for in vitro experiments. RT-qPCR and Western blot were applied for gene expression detections. Targets of miR-141-3p were predicted from starBase. The MTT and flow cytometric assays were performed to determine cell growth and apoptosis rates. The cellular glutamine metabolism was monitored by glutamine uptake assay and the glutaminase [GLS] activity assay.

Results: We reported that miR-141-3p were significantly downregulated in osteosarcoma tissues and cells. Overexpression of miR-141-3p suppressed OS cell growth and sensitized OS cells to cisplatin. In addition, glutamine metabolism was significantly increased in osteosarcoma. We characterized that GLS played oncogenic roles in osteosarcoma and validated GLS was a direct target of miR-141-3p in OS cells. Rescue experiments consistently demonstrated that miR-141-3p-promoted cisplatin sensitivity was achieved by targeting GLS directly.

Conclusion: Overall, our findings revealed new molecular mechanisms of the miR-141- 3p-modulated cisplatin sensitization through targeting the GLS-glutamine metabolism pathway. This study will contribute to developing new therapeutic approaches for the treatments of chemoresistant osteosarcoma.

Keywords: Osteosarcoma, cisplatin resistance, miR-141-3p, glutaminase, glutamine, metabolism.

[1]
Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. SICOT J 2018; 4: 12.
[http://dx.doi.org/10.1051/sicotj/2017028] [PMID: 29629690]
[2]
Czarnecka AM, Synoradzki K, Firlej W, et al. Molecular biology of osteosarcoma. Cancers (Basel) 2020; 12(8): E2130.
[http://dx.doi.org/10.3390/cancers12082130] [PMID: 32751922]
[3]
de Azevedo JWV, de Medeiros Fernandes TAA, Fernandes JV Jr, et al. Biology and pathogenesis of human osteosarcoma. Oncol Lett 2020; 19(2): 1099-116.
[PMID: 31966039]
[4]
Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014; 740: 364-78.
[http://dx.doi.org/10.1016/j.ejphar.2014.07.025] [PMID: 25058905]
[5]
Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther 2018; 18(1): 39-50.
[http://dx.doi.org/10.1080/14737140.2018.1413939] [PMID: 29210294]
[6]
Subramaniam S, Jeet V, Clements JA, Gunter JH, Batra J. Emergence of microRNAs as key players in cancer cell metabolism. Clin Chem 2019; 65(9): 1090-101.
[http://dx.doi.org/10.1373/clinchem.2018.299651] [PMID: 31101638]
[7]
Ebrahimi N, Aslani S, Babaie F, et al. MicroRNAs implications in the onset, diagnosis, and prognosis of osteosarcoma. Curr Mol Med 2020; 21: 573-88.
[PMID: 33272173]
[8]
Lei W, Yan C, Ya J, Yong D, Yujun B, Kai L. MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4. BMC Cancer 2018; 18(1): 631.
[http://dx.doi.org/10.1186/s12885-018-4460-0] [PMID: 29866054]
[9]
Pu Y, Zhao F, Li Y, et al. The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. BMC Cancer 2017; 17(1): 45.
[http://dx.doi.org/10.1186/s12885-016-3002-x] [PMID: 28073349]
[10]
Liang Z, Li X, Liu S, Li C, Wang X, Xing J. MiR-141-3p inhibits cell proliferation, migration and invasion by targeting TRAF5 in colorectal cancer. Biochem Biophys Res Commun 2019; 514(3): 699-705.
[http://dx.doi.org/10.1016/j.bbrc.2019.05.002] [PMID: 31078266]
[11]
Zhou Y, Zhong JH, Gong FS, Xiao J. MiR-141-3p suppresses gastric cancer induced transition of normal fibroblast and BMSC to cancer-associated fibroblasts via targeting STAT4. Exp Mol Pathol 2019; 107: 85-94.
[http://dx.doi.org/10.1016/j.yexmp.2018.11.014] [PMID: 30502321]
[12]
Hirahata M, Osaki M, Kanda Y, et al. PAI-1, a target gene of miR-143, regulates invasion and metastasis by upregulating MMP-13 expression of human osteosarcoma. Cancer Med 2016; 5(5): 892-902.
[http://dx.doi.org/10.1002/cam4.651] [PMID: 26817521]
[13]
Li T, Le A. Glutamine metabolism in cancer. Adv Exp Med Biol 2018; 1063: 13-32.
[http://dx.doi.org/10.1007/978-3-319-77736-8_2] [PMID: 29946773]
[14]
Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer 2016; 16(10): 619-34.
[http://dx.doi.org/10.1038/nrc.2016.71] [PMID: 27492215]
[15]
Obrist F, Michels J, Durand S, et al. Metabolic vulnerability of cisplatin-resistant cancers. EMBO J 2018; 37(14): e98597.
[http://dx.doi.org/10.15252/embj.201798597] [PMID: 29875130]